For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the arrival of Tafamidis and the formulated version represents a significant advancement . These innovative therapies protect the transthyretin protein, preventing its damaging build-up and allevi